Ciphergen Equalizer Bead Technology Paper Recognized as ScienceDirect TOP25 Hottest Articles by Elsevier
June 02 2006 - 10:00AM
PR Newswire (US)
Paper Highlights Role of Novel Proteomic Technologies in
Identifying New Markers FREMONT, Calif., June 2
/PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH)
announced today the receipt of a diploma from Elsevier publishers
recognizing a recent paper as one of the top five papers downloaded
from the website of the journal Clin Chim Acta. The paper titled,
"Proteome Analysis in the Clinical Chemistry Laboratory; Myth or
Reality?" provides an exhaustive overview of available technologies
for proteomic analysis, particularly for the discovery of novel
disease biomarkers. The paper describes the challenges of the
dynamic range of the proteome, and demonstrates how Ciphergen's
Equalizer Bead technology can help address this challenge. The
paper was authored by Dr. Pier Giorgio Righetti at the University
of Verona and Dr. Egisto Boschetti at Ciphergen, and their
colleagues. "The popularity of this paper demonstrates the urgent
need for new technologies that can aid scientists and clinicians in
the discovery of new protein markers. The novel technologies, such
as Equalizer Beads, that we are developing will enable our
collaborators and us to achieve this goal and develop novel
high-value diagnostic tests," said Gail S. Page, President and CEO.
Copies of the manuscript can be downloaded at
http://www.sciencedirect.com/science . About Ciphergen Ciphergen is
dedicated to the discovery of protein biomarkers and panels of
biomarkers and their development into protein molecular diagnostic
tests that improve patient care; and to providing collaborative
R&D services through its Biomarker Discovery Center(R)
laboratories for biomarker discovery for new diagnostic tests as
well as pharmacoproteomic services for improved drug toxicology,
efficacy and theranostic assays. Ciphergen develops, manufactures
and markets a family of ProteinChip(R) Systems and services for
clinical, research and process proteomics applications. ProteinChip
Systems enable protein discovery, validation, identification and
assay development to provide researchers with predictive,
multi-marker assay capabilities and a better understanding of
biological function at the protein level. Additional information
about Ciphergen can be found at http://www.ciphergen.com/. Safe
Harbor Statement Note Regarding Forward-Looking Statements: For
purposes of the Private Securities Litigation Reform Act of 1995
(the "Act"), Ciphergen disclaims any intent or obligation to update
these forward-looking statements, and claims the protection of the
Safe Harbor for forward-looking statements contained in the Act.
Examples of such forward-looking statements include statements
regarding the usefulness of Ciphergen technologies in the discovery
of protein biomarkers and the ability of Ciphergen to use such
biomarkers in the creation of diagnostic tests. Actual results may
differ materially from those projected in such forward-looking
statements due to various factors, including the risk that
Ciphergen may not be able to develop diagnostic tests based on the
discoveries of biomarkers. Investors should consult Ciphergen's
filings with the Securities and Exchange Commission, including its
Form 10-K dated March 17, 2006, for further information regarding
these and other risks of the Company's business. NOTE: Ciphergen,
ProteinChip and Biomarker Discovery Center are registered
trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen
Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of
Ciphergen Biosystems, Inc., +1-510-505 2297 Web site:
http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From May 2024 to Jun 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2023 to Jun 2024